The United Kingdom diabetes market size was valued at USD 1.72 Billion in 2025 and is projected to reach USD 2.30 Billion by 2034, exhibiting a CAGR of 3.14% during the forecast period 2026-2034. Rising type-2 diabetes prevalence, the ageing UK population, growing adoption of GLP-1 therapies such as semaglutide and tirzepatide, NHS drug reimbursement expansion under NICE’s 2024 guideline updates, and steady uptake of biosimilar insulin analogues are driving the UK diabetes market growth. Insulin leads the product segment at 53.3% in 2025, while Oral Antidiabetics hold 46.7%. Retail Pharmacies dominate distribution at 53.6% in 2025, supported by the UK’s strong community pharmacy network.
This new report “United Kingdom Diabetes Market Report: 2026-2034” provides an analytical and statistical insight into the UK diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in UK. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the UK diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the UK diabetes market in any form.
This new report “United Kingdom Diabetes Market Report: 2026-2034” provides an analytical and statistical insight into the UK diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in UK. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the UK diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the UK diabetes market in any form.
What this Report Achieves:
Comprehensive situation analysis of the UK diabetes epidemiology and its dynamics:
Focus of the Analysis:
Historical, current and future prevalence of diabetes in UK
Historical, current and future prevalence of type-1 and type-2 diabetes in UK
Historical, current and future prevalence of diabetes in the urban and rural regions in UK
Historical, current and future prevalence of diabetes among males and females in UK
Historical, current and future prevalence of diabetes among various age groups in UK
Historical, current and future diagnosis rates for diabetes in UK
Historical, current and future drug treatment rates for diabetes in UK
Comprehensive situation analysis of the UK Oral Antidiabetics market and its dynamics:
Focus of the Analysis:
Performance of the Oral Antidiabetics market in UK
Performance of key classes
Performance of key players
Market outlook
Comprehensive situation analysis of the UK Insulin market and its dynamics:
Focus of the Analysis:
Performance of the Insulin market in UK
Performance of key classes
Performance of key players
Market outlook
KEY QUESTIONS ANSWERED IN THIS REPORT
- What is the UK diabetes market size in 2025?
- What is the UK diabetes market forecast through 2034?
- Which segment leads the UK diabetes market?
- Which distribution channel dominates the UK diabetes market?
- What is driving UK diabetes market growth?
- What is the fastest-growing channel in the UK diabetes market?
- Who are the top companies in the UK diabetes market?
- How are biosimilars affecting the UK diabetes market?
- What role do GLP-1 agonists play in the UK diabetes market?
- How does NICE affect the UK diabetes market?
- What is the role of digital pharmacy in UK diabetes care?
Table of Contents
1 Preface3 Executive Summary
2 Scope and Methodology
4 Introduction
5 Diabetes Disease Overview
6 UK Diabetes Epidemiology
7 UK Diabetes Market
8 Competitive Landscape
List of Figures
Companies Mentioned
- Novo Nordisk A/S
- Sanofi
- Eli Lilly and Company
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Merck & Co. Inc.
- Biocon Limited
